GSK aims for biotech attitude at R&D ops

Biotech thinking is in. The Big Pharma mindset is out. And you only have to stroll through the halls of GlaxoSmithKline's shrinking R&D ops to find telltale signs of the shift in development strategies. The Wall Street Journal's Jeanne Whalen took a tour and found no shortage of anecdotes about GSK's move to break its research unit into small groups in order to develop that lean-and-mean biotech attitude needed to move through the clinic quickly. The British scientist Kevin Lee even...